关于儿童使用长效生长激素的最新情况
Margaret Cristina da Silva Boguszewski1, Cesar Luiz Boguszewski2
1Department of Pediatrics.
Current opinion in pediatrics
|May 15, 2024
概括
长效生长激素 (LAGH) 配方为治疗儿童生长激素缺乏症提供了一个新的选择,其疗效与每日注射相似. 需要进一步的现实世界数据来确认好处和成本效益.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 每日注射复合人体生长激素 (rhGH) 在临床实践中存在挑战.
- 长效生长激素 (LAGH) 配方已被开发来应对这些挑战.
- 现在已经批准了几种LAGH配方用于治疗生长激素缺乏症儿童.
研究的目的:
- 提供对LAGH发展的历史概述.
- 批判性地分析有关已批准的儿童LAGH治疗的现有文献.
- 评估LAGH作为每日rhGH治疗的潜在替代品.
主要方法:
- 对已批准的LAGH配方的临床试验数据的审查.
- 对LAGH和每天的rhGH进行比较研究的分析.
- 从已发表的文献中评估安全性和有效性概况.
主要成果:
- 在促进儿科患者的线性生长方面,LAGH疗法表现为与每日的rhGH相比非劣.
- 在LAGH和每日RhGH治疗组之间,不良事件发生率相似.
- 该审查涵盖了目前为儿科使用批准的五种LAGH配方.
结论:
- 需要真实世界的数据来确定LAGH的最佳患者选择.
- 需要进一步研究不同LAGH化合物的合规性,长期疗效和安全性.
- 各种环境中的成本效益和比较效益仍需确定.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Insulin Formulations: Types and Delivery
191
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
191
Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
Nature and Nurture
20.5K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.5K


